down arrow

Matinas BioPharma Holdings, Inc.

  • Market Cap: N/A
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US5768101058
USD
0.67
-0.08 (-10.77%)

Dec 23

ASE

 Click here to see other stocks
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

0.670.74

52 Week

0.473.09
Valuation
Technical
Day's Volume

CASH

2.28 k

Shareholding (Mar 2025)

FII

15.31%

Held by 6 FIIs

DII

81.52%

Held by 3 DIIs

Promoter

0.00%

How big is Matinas BioPharma Holdings, Inc.?

22-Jun-2025

As of Jun 18, Matinas BioPharma Holdings, Inc. has a market capitalization of 4.65 million, with net sales of 0.00 million and a net profit of -20.09 million over the latest four quarters. The company reported shareholder's funds of 7.59 million and total assets of 12.64 million as of Dec 24.

Market Cap: As of Jun 18, Matinas BioPharma Holdings, Inc. has a market capitalization of 4.65 million, categorizing it as a Micro Cap company.<BR><BR>Recent Quarterly Performance: For the latest four quarters, Matinas BioPharma reported net sales of 0.00 million and a net profit of -20.09 million.<BR><BR>Balance Sheet Snapshot: As of Dec 24, the company reported shareholder's funds of 7.59 million and total assets of 12.64 million.

Read More

What does Matinas BioPharma Holdings, Inc. do?

22-Jun-2025

Matinas BioPharma Holdings, Inc. is a micro-cap biopharmaceutical company focused on developing novel pharmaceutical products. As of March 2025, it reported a net loss of $2 million and has a market cap of $4.65 million.

Overview: <BR>Matinas BioPharma Holdings, Inc. is a development stage biopharmaceutical company focused on identifying and developing novel pharmaceutical products within the Pharmaceuticals & Biotechnology industry, categorized as a micro-cap company.<BR><BR>Financial Snapshot: <BR>Most recent Net Profit: -2 Million (Quarterly Results - Mar 2025) <BR>Market cap: USD 4.65 Million (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: NA (Loss Making) <BR>Industry P/E: NA <BR>Dividend Yield: 0.00% <BR>Debt Equity: -0.99 <BR>Return on Equity: -256.46% <BR>Price to Book: 0.74<BR><BR>Contact Details: <BR>Address: SUITE 302, 1545 ROUTE 206 SOUTH, BEDMINSTER NJ : 7921 <BR>Tel: ['1 908 4431860', '1 415 7224563'] <BR>Fax: 1 302 6365454 <BR>Website: https://www.matinasbiopharma.com/

Read More

Who are in the management team of Matinas BioPharma Holdings, Inc.?

22-Jun-2025

As of March 2022, the management team of Matinas BioPharma Holdings, Inc. includes Mr. Herbert Conrad (Independent Chairman), Mr. Jerome Jabbour (CEO), Mr. Patrick LePore (Independent Vice Chairman), and several independent directors: Dr. Eric Ende, Ms. Natasha Giordano, Mr. James Scibetta, and Dr. Matthew Wikler. This team combines executive leadership with independent oversight for strategic governance.

As of March 2022, the management team of Matinas BioPharma Holdings, Inc. includes the following individuals:<BR><BR>- Mr. Herbert Conrad, Independent Chairman of the Board<BR>- Mr. Jerome Jabbour, President, Chief Executive Officer, Director<BR>- Mr. Patrick LePore, Independent Vice Chairman of the Board<BR>- Dr. Eric Ende, Independent Director<BR>- Ms. Natasha Giordano, Independent Director<BR>- Mr. James Scibetta, Independent Director<BR>- Dr. Matthew Wikler, Independent Director<BR><BR>This team comprises a mix of executive leadership and independent directors, reflecting a governance structure aimed at overseeing the company's strategic direction.

Read More

Is Matinas BioPharma Holdings, Inc. overvalued or undervalued?

25-Jun-2025

As of May 9, 2024, Matinas BioPharma Holdings, Inc. is considered overvalued and does not qualify for a favorable valuation grade due to significant financial challenges, including a low return on equity of -256.46% and poor performance compared to peers and the S&P 500.

As of 9 May 2024, Matinas BioPharma Holdings, Inc. has moved from a valuation grade of risky to does not qualify. The company is currently considered overvalued given its significant financial challenges, including a price-to-book value of 0.75 and an EV to EBITDA ratio of 0.09, which indicate poor financial health and operational inefficiency. The return on equity (ROE) is alarmingly low at -256.46%, highlighting the company's struggles to generate profit from its equity base.<BR><BR>In comparison to its peers, Matinas BioPharma's valuation metrics are concerning. For instance, ASP Isotopes, Inc. has a P/E ratio of -24.0140, while ARCA biopharma, Inc. shows a P/E of -5.3909, both indicating a similarly distressed financial state. Furthermore, the company's stock has underperformed significantly over the past year, with a return of -88.56% compared to the S&P 500's gain of 10.26%, reinforcing the notion that Matinas BioPharma is overvalued in its current state.

Read More

Is Matinas BioPharma Holdings, Inc. technically bullish or bearish?

20-Sep-2025

As of September 8, 2025, Matinas BioPharma Holdings, Inc. shows a mildly bullish trend with mixed signals across different time frames, having a year-to-date return of 239.22% but a 1-year return of -50.85%, indicating conflicting indicators and longer-term underperformance.

As of 8 September 2025, the technical trend for Matinas BioPharma Holdings, Inc. has changed from bullish to mildly bullish. The weekly MACD is bullish while the monthly MACD is mildly bullish, indicating some positive momentum. The weekly RSI is bearish, contrasting with the monthly RSI which is bullish, suggesting mixed signals across time frames. The daily moving averages are bullish, supporting a short-term positive outlook. However, Bollinger Bands show a mildly bullish weekly stance but a bearish monthly stance, adding to the mixed signals. <BR><BR>In terms of performance, the stock has a year-to-date return of 239.22%, significantly outperforming the S&P 500's 12.22% during the same period, but it has underperformed over the longer term with a 1-year return of -50.85% compared to the S&P 500's 17.14%. Overall, the current technical stance is mildly bullish, but the strength is tempered by conflicting indicators and longer-term underperformance.

Read More
iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard
Icon
Unrated Stock - No Analysis Available
stock-summaryMojo Parameters
Mojo Parameters
Stock DNA
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 8 Million ()

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

-0.75

stock-summary
Return on Equity

-157.24%

stock-summary
Price to Book

1.11

Revenue and Profits:
Net Sales:
(Quarterly Results - Jun 2025)
Net Profit:
-5 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-65.46%
0%
-65.46%
6 Months
-23.86%
0%
-23.86%
1 Year
28.84%
0%
28.84%
2 Years
-93.88%
0%
-93.88%
3 Years
29.11%
0%
29.11%
4 Years
-98.71%
0%
-98.71%
5 Years
-98.63%
0%
-98.63%

Matinas BioPharma Holdings, Inc. for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions
News
Icon
No Recent News for the Company
Announcements stock-summary
Icon
No announcement available
Corporate Actions stock-summary
Icon
No corporate action available
stock-summaryKey Factors
Quality key factors stock-summary
Factor
Value
Sales Growth (5y)
0
EBIT Growth (5y)
7.80%
EBIT to Interest (avg)
-23.10
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.99
Sales to Capital Employed (avg)
0.10
Tax Ratio
0
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
28.58%
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
0.75
EV to EBIT
0.09
EV to EBITDA
0.09
EV to Capital Employed
-1.45
EV to Sales
NA
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
Negative Capital Employed
ROE (Latest)
-256.46%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bearish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bearish
Bearish
Moving Averages
Mildly Bullish (Daily)
KST
Bearish
Mildly Bearish
Dow Theory
Mildly Bearish
Mildly Bearish
OBV
No Trend
Mildly Bearish
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Mar 2025stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Foreign Institutions

Domestic Funds

Held in 5 Schemes (3.18%)

Foreign Institutions

Held by 6 Foreign Institutions (15.31%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Jun 2025 is 0.00% vs 0.00% in Mar 2025",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "QoQ Growth in quarter ended Jun 2025 is -205.88% vs 79.76% in Mar 2025",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Mar'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-1.70",
          "val2": "-1.80",
          "chgp": "5.56%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "-3.50",
          "val2": "0.30",
          "chgp": "-1,266.67%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-5.20",
          "val2": "-1.70",
          "chgp": "-205.88%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is -100.00% vs -65.62% in Dec 2023",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is -6.11% vs -9.05% in Dec 2023",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "1.10",
          "chgp": "-100.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-19.20",
          "val2": "-22.80",
          "chgp": "15.79%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "-4.20",
          "val2": "0.60",
          "chgp": "-800.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-24.30",
          "val2": "-22.90",
          "chgp": "-6.11%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "-21,684.30%",
          "chgp": "2,168.43%",
          "chgp_class": "positive"
        }
      ]
    }
  }
]
Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQstock-summary
Jun'25
Mar'25
Change(%)
Net Sales
0.00
0.00
Operating Profit (PBDIT) excl Other Income
-1.70
-1.80
5.56%
Interest
0.00
0.00
Exceptional Items
-3.50
0.30
-1,266.67%
Consolidate Net Profit
-5.20
-1.70
-205.88%
Operating Profit Margin (Excl OI)
0.00%
0.00%
NA
USD in Million.
stock-summary Compare with Peers
Net Sales

QoQ Growth in quarter ended Jun 2025 is 0.00% vs 0.00% in Mar 2025

Direction Arrows
Consolidated Net Profit

QoQ Growth in quarter ended Jun 2025 is -205.88% vs 79.76% in Mar 2025

All Quarterly Resultsstock-summary
Annual Results Snapshot (Consolidated) - Dec'24stock-summary
Dec'24
Dec'23
Change(%)
Net Sales
0.00
1.10
-100.00%
Operating Profit (PBDIT) excl Other Income
-19.20
-22.80
15.79%
Interest
0.00
0.00
Exceptional Items
-4.20
0.60
-800.00%
Consolidate Net Profit
-24.30
-22.90
-6.11%
Operating Profit Margin (Excl OI)
0.00%
-21,684.30%
2,168.43%
USD in Million.
stock-summary Compare with Peers
Direction Arrows
Net Sales

YoY Growth in year ended Dec 2024 is -100.00% vs -65.62% in Dec 2023

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Dec 2024 is -6.11% vs -9.05% in Dec 2023

All Annual Resultsstock-summary
stock-summaryCompany CV
About Matinas BioPharma Holdings, Inc. stock-summary
stock-summary
Matinas BioPharma Holdings, Inc.
Pharmaceuticals & Biotechnology
Matinas BioPharma Holdings, Inc., is a development stage biopharmaceutical company. The Company focuses on identifying and developing novel pharmaceutical products. The Company's technology utilizes lipid-crystal nano-particle cochleates to nano-encapsulate existing drugs, which is designed to make safer, more tolerable, less toxic and orally bioavailable. The Company's technology combines the use of lipids as active pharmaceutical ingredients (APIs) and the use of lipids in cochleate-shaped lipid-crystal nano-particle drug delivery vehicles. The Company’s product candidates include, MAT2203 and MAT2501.The Company's anti-infective product candidate, MAT 2203, is an application of its cochleate delivery technology to a spectrum anti-fungal drug called amphotericin B. The Company's MAT2501 is an orally administered, encochleated formulation of the spectrum IV-only aminoglycoside antibiotic agent amikacin, utilizes the Company's lipid-crystal, nanoparticle delivery technology.
Company Coordinates stock-summary
Company Details
SUITE 302, 1545 ROUTE 206 SOUTH , BEDMINSTER NJ : 7921
stock-summary
Tel: 1 908 44318601 415 7224563
stock-summary
https://www.matinasbiopharma.com/
stock-summary
Registrar Details
Stock List
ABCDEFGHIJKLMNOPQRSTUVWXYZOther
Footer Logo
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
Market
Webinars
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."